Healthy Clinical Trial
Official title:
Effects of High Protein Diet on the Large Intestine in Overweight Humans
This study aims at evaluating the consequences of a 3 weeks high protein diet on the large intestine ecosystem (microbiota, metabolites and gene expression in rectal mucosa). Those parameters will be analysed with technics including OMICs methods. After a run-in period, 42 volunteers will receive either soy or milk protein or maltodextrin as a placebo control. This trial is double blind randomized placebo-controlled paralleled design (3 arms). Longitudinal sampling will allow the comparison of parameters during the study.
High protein diets are widely used for their slimming effect. Those diets increase the
quantity of undigested protein and peptides reaching the large intestine. Microbiota
utilizes protein and peptides as substrates and produces amino-acid derived metabolites such
as short chain fatty acids, branched chain fatty acids, lactate, formate, succinate,
ammonium, hydrogen sulfide and phenolic compounds. Some of those metabolites have been shown
to be beneficial to the host whereas other could be deleterious. High protein diets may have
different effects whether based on animal or plant proteins since those two kinds of protein
have different amino acids composition and slightly different digestibility. The objective
of this study is to evaluate in overweight volunteers the consequences of high protein diets
(animal vs vegetal) vs isocaloric-normoproteic diet at the level of the large intestine and
metabolism. Firstly, composition and activity of the microbiota and the metabolites produced
in the large intestine lumen will be determined. Then, to evaluate the consequences of the
tested diets on mucosal physiology, gene expression will be analyzed in rectal biopsies and
fecal water will be tested on colonocytes cell lines. Lastly, the consequences of the diets
on host metabolism will be evaluated.
Dietary intervention
Before the study, volunteers (n=42) will provide a 3 day food record that will be utilized
by a dietician to calculate their usual energy intake. The study will start with a 2 weeks
normalization period during which the volunteers will have to eat according to menus (Fig.
1). The diet will provide to the volunteer their usual individual energy intake; and
protein, carbohydrates and fat will respectively provide 15, 50 and 35 % of the energy
intake.
At the end of this standardization period, volunteers will be randomly assigned into 3
groups (n=14) for 3 weeks (intervention period) (Fig. 1). Volunteers of the 3 groups will
follow a diet with a reduced digestible carbohydrates intake (15% of energy intake) while
undigestible carbohydrate intake will remain unchanged. The volunteers will consume 3 times
per day a dietary supplement powder that they will dissolve in water and then drink. This
supplement will provide them 15% of their energy intake. The first group will receive a
casein (animal protein) supplement so that they will have a high protein diet (protein,
carbohydrates and fat will respectively provide 30, 35 and 35 % of the energy intake). The
second group will receive a soy protein(vegetal) supplement so that they will also consume a
high protein diet (protein, carbohydrates and fat will respectively provide 30, 35 and 35 %
of the energy intake). The third group will receive a maltodextrin (digestible carbohydrate,
placebo control) supplement so that they will ingest a normoproteic diet, similar in
macronutrient composition to the standardization diet (protein, carbohydrates and fat will
respectively provide 15, 50 and 35 % of the energy intake). The dietary supplement will be
given in a double-blinded protocol. There will be no energy restriction between the
standaridization and intervention periods.
Clinical protocol
Daily, the volunteers will measure their body weight and record their food consumption and
physical activity. Once a week, they will have a phone call with a dietician to ensure
dietary compliance (Fig. 2).
At the end of the normalization period, 13 days after the beginning of the study (D13),
volunteers will collect 24h urine samples. Stool samples will be collected from the evening
of D13 to the morning of D14 . A cooler will be provided to the volunteer for storage and
transport of samples. After one night fasting, in the morning of D14, the volunteers will
come to the hospital and will bring their samples that will be immediately conditioned for
storage. Blood samples will be collected. Then, rectal biopsies will be recovered. Every
week during the intervention period, urine stool and blood will be sampled (D21, D28, D35).
At the end of the intervention period, rectal biopsies will be recovered (D35). Body weight
and blood pressure will be measured at each visit.
Analyses All measured parameters will be expressed relatively to baseline.
Dietary intake will be evaluated by dietician based on food records.
Stool samples
- Microbiota composition and functions
- Luminal metabolites composition
- pH, osmolarity, water content
- Fecal water test on HT-29 cells (colonocytes) for mitochondrial respiration,
proliferation, genotoxicity, cytotoxicity, gene expression
Urines
- Urea and creatinine assay (protein consumption marker to verify dietary compliance)
- Metabolomics
Blood
- Clinical parameters (total cholesterol, LDL and HDL cholesterol, non-esterified fatty
acids, triglycerides, glycemia, insulinemia)
- Metabolomics
Rectal biopsies
• Transcriptomic analyses
;
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06052553 -
A Study of TopSpin360 Training Device
|
N/A | |
| Completed |
NCT05511077 -
Biomarkers of Oat Product Intake: The BiOAT Marker Study
|
N/A | |
| Recruiting |
NCT04632485 -
Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
|
||
| Completed |
NCT05931237 -
Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults
|
N/A | |
| Terminated |
NCT04556032 -
Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women
|
N/A | |
| Completed |
NCT04527718 -
Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers
|
Phase 1 | |
| Completed |
NCT04107441 -
AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects
|
Phase 1 | |
| Completed |
NCT04065295 -
A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225
|
Phase 1 | |
| Completed |
NCT04998695 -
Health Effects of Consuming Olive Pomace Oil
|
N/A | |
| Completed |
NCT01442831 -
Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects
|
Phase 1 | |
| Terminated |
NCT05934942 -
A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood
|
Phase 1 | |
| Recruiting |
NCT05525845 -
Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI
|
N/A | |
| Completed |
NCT05515328 -
A Study in Healthy Men to Test How BI 685509 is Processed in the Body
|
Phase 1 | |
| Completed |
NCT05030857 -
Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects
|
Phase 1 | |
| Completed |
NCT04967157 -
Cognitive Effects of Citicoline on Attention in Healthy Men and Women
|
N/A | |
| Recruiting |
NCT04714294 -
Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers
|
Phase 1 | |
| Recruiting |
NCT04494269 -
A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls
|
Phase 1 | |
| Completed |
NCT04539756 -
Writing Activities and Emotions
|
N/A | |
| Recruiting |
NCT04098510 -
Concentration of MitoQ in Human Skeletal Muscle
|
N/A | |
| Completed |
NCT03308110 -
Bioavailability and Food Effect Study of Two Formulations of PF-06650833
|
Phase 1 |